Stem cell transplantation in multiple myeloma (0, 1, or 2)

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 93-98

  Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Multiple myeloma; Reduced intensity conditioning

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; HUMAN; INTERMETHOD COMPARISON; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T CELL DEPLETION;

HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 17144426475     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000152978.32304.37     Document Type: Review

References (30)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:1844-1845.
2. Child JA, Morgan GJ, Davies FC, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
3. Harousseau JL, Attal M. High-dose therapy in multiple myeloma. Hematol J 2003; 4:163-170. This is a concise review of the results of autologous and allogeneic stem cell transplantation in MM in 2003.
4. 2 are superior to standard melphalan/prednisone in terms of response rate, EFS, and OS. This is the first demonstration of the superiority of high-dose therapy over conventional chemotherapy in patients aged 65 to 70 years.
5. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004; 103:20-32. This comprehensive review of the current treatment of MM includes the large experience of tandem autotransplants by the Arkansas group.
6. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood 1999; 93:55-65.
7. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502. This randomized study by the IFM group shows the superiority of tandem autotransplants over single autotransplants in terms of EFS and OS. This study also suggests that only patients without a good response to one transplant will benefit from the second.
8. Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience [abstract]. Hematol J 2003; 4 (suppl 1):560.
9. Segeren CM, Sonneveld P, Van Der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144-2151. This report demonstrates that the results of randomized studies should not be published too early. The negative results shown in this paper were not confirmed by an updated analysis [10].
10. Sonneveld P, Van Der Holt B, Sergeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the prospective phase III study Hovon 24-MM [abstract]. Hematol J 2003; 4 (suppl 1):559-560.
11. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long-term survival in myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101:3849-3856. This paper is one of the contributions of the Arkansas group to the definition of prognostic factors in the context of tandem autotransplantations.
12. Shaughnessy J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Haematol 2003; 120:44-52. The authors confirm that chromosome 13 deletions are associated with poor outcome in the context of tandem autotransplants and that if abnormalities are defined by karyotype the prognosis is even poorer.
13. Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities with myeloma signature karyotype: only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122:430-440. Thanks to a large number of patients treated with tandem autotransplants, this report identifies a subgroup with a very poor prognosis despite tandem autotransplantation.
14. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy. Blood 2002; 100:1579-1583.
15. Chang H, Sloan S, Li D, et al. The t(4; 14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125:64-68. This paper confirms the adverse prognosis associated with t(4;14) in patients treated with ASCT.
16. Soverini S, Cavo M, Cellini C, et al. Cyclin D overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003; 102:1588-1594. The authors confirm, by an elegant and sensitive technique (real-time reverse transcription polymerase chain reaction), that chromosome 11 abnormalities that induce cyclin D1 overexpression are associated with a favorable outcome in patients treated with ASCT.
17. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-1571.
18. Kumar S, Lagy MR, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation in multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34:161-167. This retrospective analysis suggests that patients who do not respond to initial chemotherapy should undergo early ASCT.
19. Alyea E, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus myeloma. Bone Marrow Transplant 2003; 32:1145-1151. This retrospective study shows that autologous transplantation yields survival rates superior to those of allogeneic transplantation even after T cell depletion.
20. Lockhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study Hovon 24 MM. J Clin Oncol 2003; 21:1728-1733. This important prospective multicenter study shows the disappointing results of T cell-depleted allogeneic transplantation given as part of front-line therapy. The causes of death were both relapse and toxicity.
21. Lockhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362-4364. This large experience with donor lymphocyte infusions shows that response is related to GVHD.
22. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100:3919-3924.
23. Shaw BE, Peggs K, Bird JM, et al. The outcome of unrelated donor stem cell transplantation in patients with multiple myeloma. Br J Haematol 2003; 123:886-897. This retrospective analysis demonstrates that RIC allogeneic transplantation from unrelated donors is feasible.
24. Einsele H, Shäfer HJ, Hebart H, et al. Follow-up of patients with progressive myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121:411-418. This is one of the first series of patients with MM treated with RIC allogeneic transplantation.
25. Anagnostopoulos A, Aleman A, Giralt S. Non myeloablative reduced-intensity transplantation in multiple myeloma. Semin Oncol 2004; 31:33-36. A summary of the experience at M.D. Anderson with RIC allogeneic transplantation in MM.
26. Badros A, Barlogie B, Spegel E, et al. Improved outcomes of allogeneic transplantation in high-risk multiple myeloma patients after non myeloablative conditioning. J Clin Oncol 2002; 20:1295-1303.
27. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100:3919-3924.
28. 2 plus autologous transplantation followed by RIC allogeneic transplantation. Although the follow-up time is still short, the encouraging results justify further studies designed to evaluate the impact of this strategy.
29. Moreau P, Garban F, Façon T, et al. Preliminary results of IFM9903 and IFM9904 protocols comparing autologous followed by miniallotransplantation and double autologous transplantation in high-risk de novo multiple myeloma [abstract]. Blood 2003; 102:43a.
30. Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103:4056-4061. This important study shows the negative impact of chromosome 13 deletions on the outcome after RIC allogeneic transplantation.